Analysts Are Bullish on These Healthcare Stocks: Elanco Animal Health (ELAN), Eli Lilly & Co (LLY)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elanco Animal Health (ELAN – Research Report), Eli Lilly & Co (LLY – Research Report) and Design Therapeutics (DSGN – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elanco Animal Health (ELAN)
UBS analyst Andrea Alfonso maintained a Buy rating on Elanco Animal Health today and set a price target of $31.00. The company’s shares closed last Monday at $23.94.
Alfonso has an average return of
According to TipRanks.com, Alfonso is ranked #2581 out of 12122 analysts.
Elanco Animal Health has an analyst consensus of Strong Buy, with a price target consensus of $29.40, a 27.3% upside from current levels. In a report issued on February 24, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Eli Lilly & Co (LLY)
In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co, with a price target of $1500.00. The company’s shares closed last Monday at $1008.39.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1272.24, representing a 28.9% upside. In a report issued on February 24, RBC Capital also initiated coverage with a Buy rating on the stock with a $1250.00 price target.
Design Therapeutics (DSGN)
In a report released yesterday, Luca Issi from RBC Capital assigned a Buy rating to Design Therapeutics, with a price target of $14.00. The company’s shares closed last Monday at $10.37.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Design Therapeutics with a $16.00 average price target.
